Access For All
Recent advances in life-saving technologies have allowed for better health outcomes and an improved quality of life for those living with type 1 diabetes. Despite advancements, many of these technologies, like advanced glucose monitors and insulin pumps, are expensive and remain out of reach and inaccessible for Canadians. Through JDRF’s work in advocacy, we are supporting the T1D community to make their voices heard and moving towards the goal of equitable access across Canada.
The #AccessForAll Campaign was launched in 2019 to increase public and private coverage for insulin pumps and advanced glucose monitors and reduce the out-of-pocket costs of living with T1D. 2021 saw a high number of positive announcements from jurisdictions across Canada increasing public coverage of advanced glucose monitors:
British Columbia
Flash GM Coverage: Not covered
CGM Coverage: Announced in June 2021
Yukon
Flash GM Coverage: Announced in September 2020
CGM Coverage: Announced in January 2020
Saskatchewan
Flash GM Coverage: Announced in April 2021
CGM Coverage: Announced in April 2021
Alberta
Flash GM Coverage: Announced in December 2017
CGM Coverage: Announced in February 2022
Ontario
Flash GM Coverage: Announced in November 2021
CGM Coverage: Announced in March 2022
Manitoba
Flash GM Coverage: Announced in September 2021
CGM Coverage: Announced in September 2021
Québec
Flash GM Coverage: Announced in 2019
CGM Coverage: Announced in May 2021
PEI
Flash GM Coverage: Announced in May 2022
CGM Coverage: Announced in May 2022
Since the launch of #AccessForAll in 2019, new coverage announcements have been made in 7 provinces and 1 territory, impacting 199,500 lives. This coverage is helping those living with T1D save out of pocket costs on devices. Per year, CGMs can range from $3,000-$6,000, Flash GMs approximately $2,500 and insulin pumps from $6,000-$8,000.
While these announcements are significant for the T1D community, coverage is limited by age in many instances and more progress on public coverage needs to be made in the Atlantic region. Patient choice is also a significant issue that needs to be addressed. As the campaign continues, JDRF remains committed to advocating on behalf of every Canadian impacted by T1D to make these technologies affordable and accessible for everyone.
29 meetings with elected officials
614 letters sent by JDRF and our community of advocates